We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Zehra
Yilmaz
zehra.yilmaz@nhs.net
Prof
Ian
Wilkinson
ibw20@medschl.cam.ac.uk
Cambs
Cardiovascular
cambs.cardiovascular@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
Chronic lower respiratory diseases
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
People living with chronic obstructive pulmonary disease (COPD) may experience worsening of symptoms such as shortness of breath, coughing, and wheezing in addition to changes that may be expected for having COPD. The worsening of symptoms is called exacerbations or flare-ups, and can be debilitating and frightening, requiring additional treatment, often with azithromycin. This is an antibiotic medicine that also has anti-inflammatory properties. It is prescribed as long-term prevention to reduce the risk of flare-ups.
Some people may be affected by side effects from azithromycin. Antibiotic resistance is another concern, especially when using azithromycin for prevention rather than to treat active infection. We currently don’t know whether to advise people to stop taking
azithromycin once COPD has stabilised or stop it over the summer when fewer flare-ups happen. We also don’t know if azithromycin is more effective in some people or more likely to cause side effects in others. Given these uncertainties, it is challenging to know how best to use azithromycin in managing COPD.
Azithromycin is a valuable antibiotic, and we want to prescribe it where it has benefit but we want to avoid unnecessary side effects and reduce the chances of bacteria becoming resistant to it.
The purpose of this trial is to be able to gain results to answer these questions. We want to establish the effects of stopping azithromycin in people whose COPD has stabilised, who have been taking it for at least 3 months over the previous 12 months to reduce COPD exacerbations.
In this trial, we will compare continuing azithromycin with stopping it completely. We will compare the effects of these two treatments in the trial on flare-ups, symptoms and quality of life and also find out what factors may affect how individual participants respond to them.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Drug;
You can take part if:
You may not be able to take part if:
Electrocardiograms (ECGs) will not be a trial assessment nor entry requirement. The presence of any of the following will preclude participant inclusion: • Known hypersensitivity or allergy to any of the trial drugs or excipients (e.g. known allergic reaction/hypersensitivity to tartrazine*, known allergic reaction to aspirin**, or known diagnosis of aspirin induced asthma);• Current breast feeding, pregnancy or planned pregnancy during the trial.• Any medical history or clinically relevant abnormality that makes patient ineligible for inclusion because of a safety concern relating to continuing or discontinuing azithromycin or other considerations.• Known immunodeficiency requiring immunoglobulin/specific antibody therapy.• Azithromycin prophylaxis prescribed for non-COPD condition. • Active participation in COPD CTIMP.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Zehra
Yilmaz
zehra.yilmaz@nhs.net
Prof
Ian
Wilkinson
ibw20@medschl.cam.ac.uk
Cambs
Cardiovascular
cambs.cardiovascular@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 55548
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
